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Abstract
Little is known whether genetic variants identified in genome-wide association studies interact to increase bladder cancer 
risk. Recently, we identified two- and three-variant combinations associated with a particular increase of bladder cancer 
risk in a urinary bladder cancer case–control series (Leibniz Research Centre for Working Environment and Human Factors 
at TU Dortmund (IfADo), 1501 cases, 1565 controls). In an independent case–control series (Nijmegen Bladder Cancer Study, 
NBCS, 1468 cases, 1720 controls) we confirmed these two- and three-variant combinations. Pooled analysis of the two 
studies as discovery group (IfADo-NBCS) resulted in sufficient statistical power to test up to four-variant combinations 
by a logistic regression approach. The New England and Spanish Bladder Cancer Studies (2080 cases and 2167 controls) 
were used as a replication series. Twelve previously identified risk variants were considered. The strongest four-variant 
combination was obtained in never smokers. The combination of rs1014971[AA] near apolipoprotein B mRNA editing enzyme, 
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Introduction
Twin studies have suggested that approximately 30% of urinary 
bladder carcinomas (UBC) can be attributed to genetic predis-
position (1). Recently, genome-wide association studies have 
identified genetic variants at 15 locations associated with UBC 
risk (2). However, the identified variants show very small odds 
ratios (ORs) ranging between 1.11 and 1.24 (3). An exception is 
the homozygous deletion variant of glutathione S-transferase M1 
(GSTM1) with an OR ranging between 1.28 and 1.70 in large stud-
ies with a mean OR of about 1.43 in Caucasians (4–8).
Relatively little is known whether the identified genetic vari-
ants interact to modulate UBC risk (9). An open question is to 
which extent the common occurrence of several risk variants in 
an individual enhances risk. Recently, two large studies used a 
weighted allele score (or polygenic risk score) for each individ-
ual to model the consequences of common occurrence of risk 
alleles (10, 11). In the approach of these two studies, each ana-
lysed variant was assigned a score from zero to two risk alleles, 
which were summed to an overall weighted score for each indi-
vidual. Weights were based on the estimated OR of each vari-
ant. Subsequently, ORs of the score quartiles were estimated. 
Analysis of 12 variants in the study group of García-Closas et al. 
by this technique resulted in an OR of 2.94 for the highest scores 
(>75% quantile) compared with the lowest (<25% quantile) (11). 
Similarly, analysis of seven single nucleotide polymorphism 
(SNPs) in a Chinese study group resulted in an OR of 2.58 (>75 
versus <25% quantile) (10). A  limitation of this weighted allele 
score approach is that it does not identify the specific genetic 
variants that in combination enhances UBC risk as it does not 
model particular interactions of SNPs. Therefore, in 2012, our 
group applied a logistic regression approach in which all pos-
sible combinations of seven high-risk variants were considered 
(12, 13). This approach identified specific three-variant combina-
tions, where carriers of three high-risk alleles had higher ORs 
than carriers of only one of the alleles (12).
A limitation of this study in the Leibniz Research Centre 
for Working Environment and Human Factors at TU Dortmund 
(IfADo) case–control series in 2012 was that an independent 
study group for replication was not available. Also, higher order 
than three-variant combinations could not be studied because 
the case numbers in individual risk combination subgroups 
became smaller than 100, which did not allow analysis with 
sufficient statistical power. Meanwhile, the Nijmegen Bladder 
Cancer Study (NBCS), an independent ongoing case–control 
series comprising 1468 cases and 1720 controls (in the present 
analysis), has become available for this purpose (14–18). In the 
present study, we used this independent group to replicate the 
three-variant combinations previously identified in the total 
IfADo case–control series. In addition, the IfADo and NBCS case-
control series were combined to achieve sufficiently high case 
numbers to identify four-variant combinations. These four-way 
combinations were further explored in the New England and 
Spanish Bladder Cancer Studies (6, 19–21).
Materials and methods
We used 2969 cases and 3285 controls from two case–control series in 
Germany (the multicentric IfADo case–control series, 1501 cases/1565 
controls) and the Netherlands (NBCS, 1468 cases/1720 controls) with com-
plete genotype data for the 12 investigated genetic variants as a discov-
ery group and 2080 cases and 2167 controls from the New England and 
Spanish Bladder Cancer Studies with complete genotype data as a replica-
tion series (Table 1, Supplementary Table 1, is available at Carcinogenesis 
Online).
IfADo case–control series
In total, 1501 confirmed UBC cases and 1565 controls without malignant 
disease of European descent of four case–control series from Germany 
and Hungary were collected by the Leibniz Research Centre for Working 
Environment and Human Factors at TU Dortmund (IfADo). All par-
ticipants provided written informed consent. Details are given in the 
Supplementary Materials and Methods, available at Carcinogenesis Online, 
and elsewhere (22).
Genotypes of rs11892031[A/C], rs1495741[A/G], rs1058396[A/G], 
rs17674580[C/T], rs2294008[C/T], rs2978974[A/G], rs1014971[A/G], 
rs710521[A/G], rs798766[C/T], rs8102137[C/T] and rs9642880[G/T] were 
detected via TaqMan® Assay (23). The homozygous GSTM1 deletion was 
detected by the amplification of the GSTM1 DNA sequence segment with 
218 bp by means of PCR (24–26). Details are given in the Supplementary 
Materials and Methods, available at Carcinogenesis Online.
Abbreviations 
APOBEC3A  apolipoprotein B mRNA editing enzyme, catalytic   
 polypeptide-like 3A
CBX6   chromobox homolog 6
CCNE1   cyclin E1
CI  confidence interval
FGFR3  fibroblast growth factor receptor 3
GSTM1  glutathione S-transferase M1
IfADo  Leibniz Research Centre for Working   
 Environment and Human Factors at TU Dortmund
LR  likelihood ratio
MYC  v-myc avian myelocytomatosis viral oncogene homolog
NAT2  N-acetyltransferase 2
NBCS  Nijmegen Bladder Cancer Study
NBS  Nijmegen Biomedical Study
OR  odds ratio
PSCA  prostate stem cell antigen
SLC14A1  solute carrier family 14 (urea transporter), member 1  
 (Kidd blood group)
SNP  single nucleotide polymorphism
TACC3  transforming, acidic coiled-coil containing protein 3
TP63  tumor protein p63
UBC  urinary bladder cancer.
UGT1A  UDP glucuronosyltransferase 1 family, polypeptide  
 A complex locus
catalytic polypeptide-like 3A (APOBEC3A) and chromobox homolog 6 (CBX6), solute carrier family 1s4 (urea transporter), member 1 
(Kidd blood group) (SLC14A1) exon single nucleotide polymorphism (SNP) rs1058396[AG, GG], UDP glucuronosyltransferase 1 
family, polypeptide A complex locus (UGT1A) intron SNP rs11892031[AA] and rs8102137[CC, CT] near cyclin E1 (CCNE1) resulted 
in an unadjusted odds ratio (OR) of 2.59 (95% CI = 1.93–3.47; P = 1.87 × 10−10), while the individual variant ORs ranged only 
between 1.11 and 1.30. The combination replicated in the New England and Spanish Bladder Cancer Studies (ORunadjusted = 
1.60, 95% CI = 1.10–2.33; P = 0.013). The four-variant combination is relatively frequent, with 25% in never smoking cases 
and 11% in never smoking controls (total study group: 19% cases, 14% controls). In conclusion, we show that four high-risk 
variants can statistically interact to confer increased bladder cancer risk particularly in never smokers.
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NBCS
In the current study, we used data of 1468 cases with primary UBC from 
the NBCS and 1720 controls from the Nijmegen Biomedical Study (NBS). 
The combined NBS-NBCS served as the Dutch discovery population in pre-
vious UBC genome-wide association studies (14–18).
Genotypes of rs11892031[A/C], rs1495741[A/G], rs1058396[A/G], 
rs2294008[C/T], rs2978974[A/G], rs1014971[A/G], rs710521[A/G], rs798766[C/T], 
rs8102137[C/T] and rs9642880[G/T] were determined using the Illumina 
HumanCNV370 BeadChip as described elsewhere (14). Genotypes of 
rs17674580[C/T] were imputed using the IMPUTE v2.1 software as described 
elsewhere (14). GSTM1 copy number variation status was determined by an 
Applied Biosystems TaqMan Copy Number assay (Assay ID: Hs02575461_cn).
New England and Spanish Bladder Cancer Studies
This published case–control series includes 2080 cases and 2167 controls as 
described previously (6, 19–21). Information on 10 genotypes determined in 
the IfADo and NBCS was also available from the New England and Spanish 
Bladder Cancer Studies. In case of the solute carrier family 14 (urea transporter), 
member 1 (Kidd blood group) (SLC14A1) SNPs rs1058396 and rs17674580, the 
SNPs rs10775480 and rs10853535 were used as proxies (r2 = 0.75 and r2 = 0.66; 
data from 1000 Genomes Project, CEU (phase 3), ensemble genome browser 
version 87). A summary of study group characteristics is given in Table 1.
Statistical analysis
Analyses were performed in the discovery group (total study group: IfADo 
and NBCS combined) and stratified for subgroups defined by smoking 
habits: never (less than 100 cigarettes/lifetime), former (stopped smok-
ing before first diagnosis of UBC/recruitment), current (still smoking 
at UBC diagnosis/recruitment or just stopped smoking, for details, see 
Supplementary Materials and Methods, available at Carcinogenesis Online) 
and ever smokers (former and current smokers combined). ‘Unadjusted’ 
analyses were performed using asymptotic chi-squared tests, ORs and 
95% confidence intervals (95% CIs). Logistic regression and the Wald test 
adjusted for age, gender, smoking habits (if applicable) and study site (if 
applicable) were used for ‘adjusted’ analyses. Unadjusted and adjusted 
effects of ‘single variants’ on UBC risk were analysed in the complete study 
group, in the subgroups defined by smoking habits and separately in the 
IfADo and in the Nijmegen study group. SNPs were analysed assuming a 
recessive, dominant and additive mode of inheritance of the minor allele.
We used the NBCS to replicate the results of a previous study in the 
IfADo case–control series on seven variants (GSTM1, rs11892031[A/C], 
rs710521[A/G], rs1495741[A/G], rs9642880[G/T], rs8102137[C/T] and 
rs1014971[A/G]) (12). The frequency of the combinations in NBCS, unad-
justed P values, ORs and 95% CIs were estimated for the 10 best two- and 
three-variant combinations found in the total IfADo study group and in 
the subgroups defined by smoking habits. To avoid spurious findings, we 
considered results as relevant if combinations were present in at least 100 
cases and 100 controls from NBCS.
To investigate relevant combinations of 12 variants in the ‘combined 
IfADo and Nijmegen study group’, we generated four binary variables for 
each of the 11 SNPs as described previously (12). These variables coded 
either for a dominant or a recessive mode of inheritance of the minor 
allele or the respective complements which are necessary to define all 
combinations of dominant and recessive genotypes. So, we defined for an 
SNP with major [A] and minor [B] alleles the risk and reference genotypes:
(i)  dominant [B]: AB and BB (risk) versus AA (reference),
(ii)   complement of dominant [B]: AA (risk) versus AB and BB (reference),
(iii)  recessive [B]: BB (risk) versus AA and AB (reference) and
(iv)  complement of recessive [B]: AA and AB (risk) versus BB (reference).
Two binary variables encoded either the GSTM1 null or the GSTM1 present 
genotype as risk factor. We used these 46 binary variables to define vari-
ant combinations. The ‘genotype at risk’ of a combination was defined as 
presence versus absence (reference) of a particular variant combination. 
P values (unadjusted) of the asymptotic chi-squared tests were computed 
for all two-, three- and four-variant combinations and used as an ordering 
criterion. The 10 lowest nominal P values identified the 10 best one- to 
four-variant combinations in the total study group and in the smoking 
habits subgroups. The analyses were restricted to combinations with a 
Table 1. Study group characteristics of the discovery and replication series
Discovery series Replication series
IfADo NBCS Combined
New England and 
Spanish Bladder Cancer 
Studies
Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%) Cases (%)
Controls 
(%)
Gender
 Female 305 (0.20) 570 (0.36) 265 (0.18) 864 (0.50) 570 (0.19) 1434 (0.44) 353 (0.17) 407 (0.19)
 Male 1196 (0.80) 995 (0.64) 1189 (0.81) 843 (0.49) 2385 (0.80) 1838 (0.56) 1727 (0.83) 1760 (0.81)
 Missing 0 (0.00) 0 (0.00) 14 (0.01) 13 (0.01) 14 (0.01) 13 (0.00) 0 (0.00) 0 (0.00)
 Total 1501 1565 1468 1720 2969 3285 2080 2167
Smoking habits
 Ever 1109 (0.74) 890 (0.57) 960 (0.65) 1246 (0.72) 2069 (0.70) 2136 (0.65) 1696 (0.82) 1360 (0.63)
 Current 404 (0.27) 297 (0.19) 272 (0.19) 362 (0.21) 676 (0.23) 659 (0.20) 776 (0.37) 428 (0.20)
 Former 705 (0.47) 593 (0.38) 688 (0.47) 884 (0.51) 1393 (0.47) 1477 (0.45) 920 (0.44) 932 (0.43)
 Never 300 (0.20) 658 (0.42) 106 (0.07) 457 (0.27) 406 (0.14) 1115 (0.34) 305 (0.15) 688 (0.32)
 Missing 92 (0.06) 17 (0.01) 402 (0.27) 17 (0.01) 494 (0.17) 34 (0.01) 79 (0.04) 119 (0.06)
Age
 Min-max 20–95 20–100 25–93 27–79 20–95 20–100 22–77 20–76
 Median (IQR) 68 (16) 67 (18) 64 (13) 63 (15) 66 (14) 65 (16) 67 (14) 66 (14)
 Mean (SD) 66.9 (11.29) 63.13 (15.49) 62.1 (9.97) 61.51 (10.33) 64.76 (10.99) 62.28 (13.08) 65.4 (10) 64.4 (10.3)
 20–55 years 246 (0.16) 386 (0.25) 289 (0.20) 476 (0.28) 535 (0.18) 862 (0.26) 369 (0.18) 434 (0.22)
 56–64 years 366 (0.24) 303 (0.19) 358 (0.24) 501 (0.29) 724 (0.24) 804 (0.24) 457 (0.22) 477 (0.22)
 65–71 years 355 (0.24) 402 (0.26) 363 (0.25) 453 (0.26) 718 (0.24) 855 (0.26) 580 (0.28) 643 (0.30)
 72+ years 529 (0.35) 473 (0.30) 189 (0.13) 277 (0.16) 718 (0.24) 750 (0.23) 674 (0.32) 613 (0.28)
For detailed information on the analysed variants, see Supplementary Table 1, available at Carcinogenesis Online. 
IQR, interquartile range (Q75–Q25%); SD, standard deviation.
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minimum frequency of 100 cases and 100 controls in the risk and in the 
reference group.
Two separate analyses were performed for the total study group as 
well as for the smoking habits subgroups: ‘Analysis I’ comprised a detailed 
analysis of the best one- to four-variant combinations. ‘Analysis II’ of the 
10 best combinations was used to confirm the results of ‘Analysis I’ using 
a set of combinations with similarly low P values.
Analysis I
For the ‘best (lowest unadjusted P value) individual variants and two-, 
three- and four-variant combinations’ unadjusted and adjusted P values, 
ORs and 95% CIs were estimated in the discovery group (IfADo and NBCS 
combined) as well as in the independent case–control series of the New 
England and Spanish Bladder Cancer Studies.
The stability of the ORs of the best combinations was investigated by 
bootstrap sampling in the discovery group as described previously (12). 
Likelihood ratio (LR) tests were used to check whether the effect of the 
variant combinations was due to multiplicative interaction or due to 
main effects of the single variants in the combination. To test whether 
the unadjusted ORs of the k-variant combinations increase significantly 
with increasing number k of combined variants, LR tests were used adding 
successively the best single variant, the best two-, three- and four-variant 
combinations to a logistic regression model. Similarly, we used LR tests 
to check whether this increase in ORs could be achieved alone by adding 
the single variants, which were present in the best combinations, as main 
effects. Finally, we checked the relevance of addition of a main effect and 
an interaction term (multiplicative) in one step by LR tests.
Analysis II
The ‘ten best two-, three- and four-variant combinations’ were used to 
compare subgroup (never versus former and current, never versus ever 
smokers) differences regarding the frequency of the single variants in the 
k-variant combinations. Exact chi-squared tests were used to compare 
never, former and current smokers and Fisher’s exact tests for pairwise 
comparisons. Increase of the ORs with increasing number k of combined 
variants was tested using the Tukey test.
All calculations were performed using the software R, version 3.0.1 (R 
Development Core Team, 2014) and SAS/STAT, versions 9.3 and 9.4 (SAS 
Institute Inc., Cary, NC). Details of the statistical analysis are given in the 
Supplementary Materials and Methods.
Results
Replication of previously reported two- and  
three-variant combinations in the NBCS
In a previous study, we reported ORs of seven genetic variants 
individually, as well as of two- and three-variant combinations 
in the IfADo study group (12, 13). In a first step of the present 
study, we performed similar analyses in the NBCS and esti-
mated the individual and combination effects. Unadjusted ORs 
of the individual variants with respect to UBC risk were similar 
between both study groups (Supplementary Tables 1B, 2). In both 
study groups, IfADo and NBCS, the lowest P values were obtained 
for the GSTM1 deletion variant and for rs9642880[TT]. Moreover, 
the previously reported strongest two- and three-variant com-
binations identified in the IfADo study group (12, 13) resulted in 
similar unadjusted ORs in the NBCS (Table 3). The top 10 two-
variant combinations identified in the IfADo study group were 
all significant also in the NBCS and the ORs obtained from both 
independent groups never differed by more than 0.14 (Table 3). 
Also, the top 10 three-variant combinations identified in the 
IfADo study group were all significant in the NBCS (Table 3). The 
analyses of the individual variants as well as two- and three-
variant combinations were repeated in the subgroups of ever, 
current, former and never smokers (Supplementary Tables 3 
and 4, available at Carcinogenesis Online). Unadjusted ORs of the 
individual variants were also quite similar between both study 
groups stratifying for smoking habits (Supplementary Table 3). In 
current and never smokers, case numbers were too low (N < 100 
per risk group in cases and in controls) to allow a comparison of 
the NBCS and the IfADo study groups (Supplementary Table 4, 
available at Carcinogenesis Online). However, in ever and former 
smokers when case and control numbers exceeded N  =  100, 
similar ORs were obtained in both study groups (Supplementary 
Table 4, available at Carcinogenesis Online). Age and sex distribu-
tions were similar between both study groups, while the NBCS 
contained less never smokers compared with the IfADo case–
control series (Table 1). In conclusion, both study groups were 
similar with respect to the influence of the individual variants 
as well as previously identified two- and three-variant combi-
nations. Therefore, a combination of the two study groups with 
the aim to identify possible four-variant combinations seemed 
justified.
Interplay of high-risk genetic variants in the 
combined IfADo-Nijmegen case–control series: 
relevance of four-variant combinations
To study the possible interactions between genetic variants 
in a larger case–control series as previously possible (12), the 
aforementioned NBCS and IfADo study groups were com-
bined resulting in a series of 2969 UBC cases and 3285 controls 
(Table 1). Data of 12 genetic variants were available in both study 
groups (Supplementary Table 1B). Five additional variants were 
analysed compared with the previous study (12). All analysed 
variants have been reported to be individually associated with 
UBC risk. In the present study, all but rs2978974 of the indi-
vidually analysed variants were significantly associated in the 
unadjusted analysis (additive genetic model, Supplementary 
Table 1B). After adjustment for age, gender and smoking habits, 
10 of them remained significant while rs2978974 (ORadditive = 1.01) 
and rs149571 (ORadditive  =  1.08) were not significant assum-
ing an additive, recessive or dominant mode of inheritance 
(Supplementary Tables 1B and 2, available at Carcinogenesis 
Online). The significant SNPs all showed ORs between 1.09 and 
1.27 (additive model; significant recessive: 1.30–1.38; significant 
dominant 1.13–1.35; Supplementary Table 2).
All possible two-, three- and four-variant combinations 
were tested, amounting to a total of 118 888 analysed effects. 
The resulting best combinations (Analysis I) showed a continu-
ous increase in unadjusted ORs for increasing variant numbers 
between one and four (Figure 1A and B; Table 3). A remarkable 
difference was obtained for smokers and never smokers. Variant 
combinations resulted in higher ORs for the never smokers. 
Ever smokers showed the lowest ORs, while former and current 
smokers ranged in between (Figure 1A and B). The total group 
(Table 3) showed similar results as the ever smokers, which can 
be explained by the fact that most of the cases (70%) were cur-
rent or former smokers. Higher than four-variant combinations 
were not tested because of small case numbers and thus sta-
tistical power limitations. For up to four-variant combinations, 
the case numbers in all subgroups were higher than N  =  100 
(Supplementary Table 8, available at Carcinogenesis Online).
Next, we tested whether an increase in the number of com-
bined variants resulted in significantly increased/decreased risk 
(Figure  2A, Supplementary Table  6A, available at Carcinogenesis 
Online). The best one- to four-variant combinations were added 
successively to the model, to test whether the resulting increases 
in the LR statistics are significant. For never smokers, significant 
increases in unadjusted ORs were obtained for all one- to four-
variant combinations added in a stepwise manner. The strongest 
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individual variant for never smokers, rs1014971[AG, GG], was sig-
nificant in a univariate logistic regression model with an LR sta-
tistic of LR = 13.16, P = 0.0003 (Figures 1C and 2A; Supplementary 
Table 6A, available at Carcinogenesis Online). Addition of the best 
two-variant combination (rs1014971, rs17674580) to the logis-
tic regression model with the best variant (rs1014971) alone 
increased the LR statistic significantly by LR = 9.92, P =  0.0016. 
Adding the best three-variant combination (rs1014971, rs1058396, 
rs11892031) to the model with the main (individual) effect and 
the two-variant combination further improved the LR statistic 
by LR = 9.75, P = 0.0018. Further inclusion of the best four-variant 
combination (rs1014971, rs1058396, rs11892031 and rs8102137), 
which now has to compete with the best individual, two- and 
three-variant combinations led to additionally improved signifi-
cance (LR = 12.01, P = 0.0005). Similar constellations were obtained 
for the former smokers and for the total group (Figure 2A). For 
the ever and for the current smokers, significant improvements 
for the LR statistics were obtained for up to three-variant com-
binations but not for a further added four-variant combination.
To analyse whether the improvement of the model fit was due 
to addition of further individual variants present in the combina-
tions or rather than interaction effects, we repeated the analysis 
adding successively the new individual variants in the two- to 
four-variant combinations as main effects in the logistic regres-
sion model (Supplementary Figure 1A and Table 6B, available at 
Carcinogenesis Online). Furthermore, we added both—interactions 
and corresponding individual variants—in each step to the model 
(Supplementary Figure 1B and Table 6C, available at Carcinogenesis 
Online). For the improvement of the model fit, the interac-
tions were more relevant than the corresponding main effects. 
Additionally, we tested the significance of each two-, three- and 
four-way interaction in the presence of the corresponding individ-
ual variants as main effects separately for each top combination 
(Supplementary Table 7). Remarkably, the four-way interactions 
were still significant in a logistic regression model that also con-
tained the corresponding main effects. For instance, in never 
smokers, the interaction term rs1014971[AA] × rs1058396[AG, GG] 
× rs11892031[AA] × rs8102137[CC, CT] (P = 0.0003) was significant 
in a common model containing also rs1014971[AA] (P = 0.4318), 
rs1058396[AG, GG] (P  =  0.1236), rs11892031[AA] (P  =  0.1207) and 
rs8102137[CC, CT] (P = 0.8005), which were not significant in pres-
ence of the interaction term (Supplementary Table 7).
The analyses of Figures 1 and 2A focussed on a single top per-
forming combination. To study if the described patterns remain 
stable for further relevant combinations, we included the ten best 
combinations for one to four variants (Analysis II) into a box plot 
analysis (Figure  2B, Supplementary Table  8). A  similar pattern 
was obtained for the ten top combinations (Figure 2B) compared 
with the best one (Figure 1). The “top ten approach” additionally 
offered the advantage that the assumed increase/decrease in the 
unadjusted ORs by increase of the number of combined variants 
could be analysed by pairwise comparisons. This illustrated that 
the increase in mean ORs from individual effects to four-vari-
ant combinations was significant for never, former and current 
smokers (Figure 2B). For the total group and ever smokers, mean 
ORs increased significantly combining up to three variants.
Different SNP combinations are relevant in ever and 
never smokers
As demonstrated in the previous paragraph, genetic variants 
interact with respect to UBC risk. Next, we analysed if the same 
or different variants were relevant in ever and never smokers. 
The variant with the lowest (unadjusted) P value in ever smokers 
was the GSTM1 deletion (Table 3). For two-variant combinations, 
SNP rs9642880 near v-myc avian myelocytomatosis viral oncogene 
homolog (MYC) together with GSTM1 deletion resulted in the low-
est P value. Next, the 5’ UTR prostate stem cell antigen (PSCA) SNP 
rs2294008 and the transforming, acidic coiled-coil containing protein 
3 (TACC3) intron SNP rs798766 amended the most significant 
combinations in ever smokers.
A completely different sequence of best variant combina-
tions was obtained for the never smokers (Table 3). The most 
significant individual variant was rs1014971 near apolipoprotein 
B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A). 
Next, rs1014971 was amended by the SLC14A1 intron SNP 
rs17674580 to form the strongest two-variant combination. The 
three-variant combination included again rs1014971 together 
Figure 1. The best combinations of up to four risk variants showed a continu-
ous increase in unadjusted ORs and a different composition in smoker sub-
groups. Combinations of 12 variants were analysed in the combined IfADo and 
Nijmegen case–control series. Unadjusted ORs of the best single variants, two-, 
three- and four-variant combinations in never and ever smokers (A) and in cur-
rent and formers smokers (B, transparent lines indicate results of never and ever 
smokers as reference) are given. The height and width of the diamonds corre-
spond to the square root of the combination frequency of controls and cases in 
the subgroup. Vertical bars indicate the 95% CIs. The overlap of polymorphisms 
in the top one- to four-variant combinations in the subgroup analyses of ever, 
current and former smokers indicated that GSTM1 is more relevant for current 
smokers in contrast to rs9642880 (MYC) that seems to be more relevant in former 
smokers (C). Associated genes are given in parenthesis.
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with the second SLC14A1 SNP (rs1058396 instead of rs17674580 
as in the two-variant combination) and the UDP glucuronosyl-
transferase 1 family, polypeptide A complex locus (UGT1A) intron 
SNP rs11892031. The four-variant combination with the lowest P 
value additionally included rs8102137 near cyclin E1 (CCNE1). In 
conclusion, considering the most significant combinations up 
to four variants, there was no overlap between ever and never 
smokers (Table 3).
Next, we further analysed the group of ever smokers (2069 
cases, 2136 controls), which consisted of former (1393 cases, 
1477 controls) and current (676 cases, 659 controls) smokers 
(Supplementary Figure 2). For both, ever and current smokers, 
the deletion of phase II detoxifying GSTM1 was identified as the 
most significant variant (Table  3). In contrast, GSTM1 was not 
among the best four-variant combinations in former smokers. 
Instead former and ever smokers overlapped in rs9642880 near 
the MYC oncogene. This suggests that quitting cigarette smok-
ing may lead to a shift in relevance for the population at risk 
from detoxifying GSTM1 to MYC, a gene which is known to act as 
a proto-oncogene. To identify the most characteristic differences 
between ever smokers (considering also former and current 
smokers) and never smokers, we analysed the top ten combina-
tions of two, three and four variants in these subgroups (Table 4, 
Supplementary Tables 8 and 9, available at Carcinogenesis Online). 
Figure 2. The increase of unadjusted ORs of up to four-variant combinations was significant for the best and the ten best combinations. (A) Impact of best one- to four-
variant combinations on UBC risk in a common logistic regression model (without adjustment for further covariates) in the combined IfADo-Nijmegen study group 
(“All”) and stratified by smoking habits (“Ever”, “Current”, “Former” and “Never” smokers). LR tests indicated that the best one- to three- (ever and current smokers) or 
four-variant combinations (all combined, former and never smokers) had a significant impact on UBC risk in a common logistic regression model. For the total study 
group as well as for all subgroups of ever (current and former smokers combined), current, former and never smokers, the LR statistic for addition of the respective 
best variant combination to a logistic regression model that contained all lower order best combinations was plotted successively, i.e. the LR statistic for the best main 
effect compared with the null model, the LR statistic for the model containing the main effect and the best two-variant combination compared with the model with 
the main effect only, etc. Significant combinations are indicated by * in case of P < 0.05 and by ** in case of P < 0.001. The best combinations are given in Table 3, the LR 
statistics and corresponding P values are given in Supplementary Table 6A. (B) The ten best unadjusted ORs of single variants, two-, three- and four-variant combina-
tions show a significant increase for increasing numbers of combined variants in smokers and never smokers. Box plots of the ten best unadjusted ORs (i.e. having the 
lowest unadjusted P value) of one- to four-variant combinations with at least 100 cases and 100 controls in the combined study group (“All”) or subgroup of ever, current, 
former and never smokers were plotted. Pairwise comparisons of the ORs of the ten best risk variants and two- to four-variant combinations were performed using 
the Tukey test. Significant increases were obtained for up to three-way (all combined, ever smokers) or four-way (current, former and never smokers) combinations, 
respectively. Significant variants and combinations are indicated by * in case of P < 0.05 and by ** in case of P < 0.001. The ten best one- to four-variant combinations are 
given in Supplementary Table 8A–E, available at Carcinogenesis Online.
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The frequency of the specific variant among the top ten combi-
nations was analysed, and significant differences between the 
four groups were analysed by a chi-squared test. This led to the 
observations that (i) GSTM1 null was significantly more frequent 
in ever and current smokers than in never smokers and more 
frequent in current compared with former smokers, support-
ing the observations in Table 3 and Figure 1C that GSTM1 lost 
its relevance when smoking had been ceased. So, GSTM1 is a 
typical “current smoker variant”, (ii) rs1014971 near APOBEC3A 
was more frequent in never smokers, compared with ever, cur-
rent and former smokers indicating that this variant is a typi-
cal “never smoker SNP” and (iii) rs9642880 near MYC was more 
frequent in ever and former smokers compared with never 
smokers and more frequent in former compared with current 
smokers. Therefore, rs9642880 is a typical “former smoker SNP” 
and seems to be relevant for cigarette smoke exposed indi-
viduals only if smoking occurred in the past with no current 
exposure.
Replication of the four-variant combinations in 
independent case–control series
Finally, we tested whether the four-variant combinations, 
particularly the combination rs1014971[AA]  ×  rs1058396[AG, 
GG]  ×  rs11892031[AA]  ×  rs8102137[CC, CT] in never smokers, 
identified in the combined IfADo-NBCS case–control series, 
could be confirmed in independent study groups. For this 
purpose, corresponding SNP data from 2080 additional blad-
der cancer cases and 2167 controls (Table  1) were available 
from the published New England and Spanish Bladder Cancer 
Studies (6, 19–21). The rs1014971[AA] × rs1058396[AG, GG] × rs1
1892031[AA] ×  rs8102137[CC, CT] combination in never smok-
ers was confirmed in the New England and Spanish Bladder 
Cancer Studies resulting in increasing (unadjusted) ORs of 
1.32 for the single variant to 1.60 for the four-variant com-
binations, respectively (Table  3B). Similarly, the four-variant 
combination in current smokers (GSTM1 null  ×  rs11892031 
[AA] ×  rs1058396[AG, GG] ×  rs1014971[AA, AG]) was confirmed 
(Table 3B). In contrast, the four-variant combination in former 
smokers (rs9642880[TT]  ×  rs8102137[CC, CT]  ×  rs1495741[AA, 
AG] × rs17674580[CC, CT]) could not be replicated, possibly due 
to the fact that former smokers are much more heterogeneous 
compared with never or current smokers. The adjusted logistic 
regression (Supplementary Table 5C) led to similar results as the 
unadjusted analysis shown in Table 3B.
Discussion
An important question is whether genetic variants can interact 
leading to higher ORs for combined high-risk alleles than the 
combination of individual variants alone. In a previous study, 
we identified three-variant combinations of seven confirmed 
UBC risk variants in the IfADo case–control series and obtained 
remarkable differences between ever and never smokers (12, 
13). In the present study, we used the NBCS to confirm the pre-
vious results. Importantly, all frequent three-variant combina-
tions could be replicated. In particular, we confirmed the results 
for the total study group and the subgroups of ever and former 
smokers. Three-variant combinations identified in current and 
never smokers were not significant, possibly because of their 
low frequency (N < 100 in cases and in controls).
As results and study group characteristics were comparable, 
we combined both case–control series to analyse up to four-var-
iant combinations with sufficient power. Moreover, five further 
UBC risk variants were added to the combination analysis. We 
restricted the analysis to combinations present in at least 100 
cases and controls to obtain robust results. We also restricted 
the analysis to four-variant combinations to avoid a bias towards 
frequent variants in higher fold combinations.
The strongest four-variant combination in never smokers 
was obtained for the high-risk alleles of rs1014971[AA] near 
APOBEC3A and chromobox homolog 6, the SLC14A1 exon SNP 
rs1058396[AG, GG], the UDP glucuronosyltransferase 1 family, polypep-
tide A complex locus intron SNP rs11892031[AA] and rs8102137[CT, 
CC] near CCNE1. The combination resulted in an unadjusted OR 
of 2.59 (95% CI = 1.93–3.47, P = 1.87 × 10−10; Table 3). This four-
variant combination was still relatively frequent, with 25 and 
11% in cases and controls, respectively. The relatively high OR of 
the combination (OR = 2.59) is remarkable considering that the 
Table 4. Variants in the ten best four-variant combinations differ between smokers and never smokers
Variants Nearest gene All
Ever 
smokers
Current 
smokers
Former 
smokers
Never 
smokers P value
P C  
versus F
P C  
versus N
P F  
versus N
P E  
versus N
GSTM1 GSTM1 9 8 10 0 0 0.0005 1.08 × 10−05 1.08 × 10−05 1.0000 0.0007
rs11892031[A/C] UGT1A 3 2 6 4 8 0.2569 0.2105 0.0031 1.08 × 10−05 1.08 × 10−05
rs1495741[A/G] NAT2 1 1 2 6 3 0.2374 0.1698 1.0000 0.0573 0.0055
rs1058396[A/G] SLC14A1 2 2 8 4 9 0.0770 0.6563 0.6285 0.1698 0.0230
rs17674580[C/T] SLC14A1 4 3 0 5 2 0.0420 0.1698 1.0000 0.3698 0.5820
rs2294008[C/T] PSCA 6 8 0 1 1 1.0000 0.0325 0.4737 0.3498 1.0000
rs2978974[A/G] PSCA 1 1 2 0 0 0.3198 1.0000 1.0000 1.0000 0.0055
rs1014971[A/G] CBX6-APOBEC3A 0 0 3 0 10 0.0005 0.4737 0.4737 1.0000 1.0000
rs710521[A/G] TP63 2 1 1 2 1 1.0000 1.0000 1.0000 1.0000 1.0000
rs798766[C/T] TACC3 2 2 1 0 2 0.7266 1.0000 1.0000 0.4737 1.0000
rs8102137[C/T] CCNE1 0 2 5 8 4 0.2689 0.3498 1.0000 0.1698 0.6285
rs9642880[G/T] MYC 10 10 2 10 0 0.0005 0.0007 0.4737 1.08 × 10−05 1.08 × 10−05
Subgroups are compared regarding the occurrence of each variant in the ten best combinations by chi-squared or fishers exact tests. Unadjusted P values, ORs and 
95% CIs of all ten best single variants, two-, three and four-variant combinations are given in Supplementary Table 8A-E, available at Carcinogenesis Online. Tests for 
the ten best two- and three-variant combinations are given in Supplementary Table 9A, B, available at Carcinogenesis Online.
P value: P value of the exact chi-squared test of homogeneity of the variant frequency in the ten best four-variant combinations in current, former and never  
smokers. The P value of Fisher’s exact test of homogeneity of the variant frequency in the ten best four-variant combinations is given for current versus former 
smokers (P C versus F), current versus never smokers (P C versus N), former versus never smokers (P F versus N) and ever versus never smokers (P E versus N).
UGT1A, UDP glucuronosyltransferase 1 family, polypeptide A complex locus, NAT2, N-acetyltransferase 2, CBX6: chromobox homolog 6; TP63, tumor protein p63.
P ≤ 0.05 are printed bold.
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individual ORs were small (OR = 1.11–1.30; Supplementary Tables 
3K, L). Furthermore, the individual variants were not significant 
(P ≥ 0.1207) in a common logistic regression model in presence 
of the four-way interaction effect (P  =  0.0003; Supplementary 
Table  7). LR tests also showed that the increase from two- to 
four-variant combinations led to a significant increase in ORs 
for each step. Next, we tested whether the four-variant combi-
nation in never smokers (rs1014971[AA] × rs1058396[AG, GG] × r
s11892031[AA] × rs8102137[CC, CT]), identified in the combined 
IfADo-NBCS study group, could be confirmed in an independ-
ent case–control series, the published New England and Spanish 
Bladder Cancer Studies (6, 19–21). The increased risk replicated 
in this group (ORunadjusted  =  1.60, 95% CI  =  1.10–2.33, P  =  0.0130) 
with similar frequencies of the combination (18% in cases, 12% 
in controls, Table 3B).
The main effect in never smokers, i.e. the most impor-
tant individual variant, of the four-variant combination was 
attributable to rs1014971[AA]. This SNP maps to an intergenic 
region close to the chromobox homolog 6 and APOBEC3A genes 
(6). Chromobox homolog genes have been reported to be involved 
in regulation of heterochromatin while APOBEC3A seems to be 
associated with genetic instability (27–29). The second SNP in 
the four-variant combination rs1058396[AG, GG] is a SLC14A1 
exon SNP (15). SLC14A1 is a urea transporter in the bladder 
which influences urine concentration as measured by specific 
gravity (30). The third variant of the four-variant combination 
was rs11892031[AA], an intron SNP of the phase II metabolism 
gene UDP glucuronosyltransferase 1 family, polypeptide A complex 
locus involved in glucuronidation (6, 31, 32). Variant number four 
in the combination was rs8102137[CC, CT] near CCNE1 (6). CCNE1 
is involved in cell cycle transition from G1 to S phase (6). In con-
clusion, the four strongest interacting SNPs for never smokers 
seem to be associated with the biological processes of chroma-
tin modification, genetic stability, detoxification and prolifera-
tion. This leads to the question why there is an interaction effect 
between these variants. We speculate that the interacting vari-
ants seem to belong to completely different biological processes, 
which may be assigned to detoxification, proliferation and DNA 
stability, thereby covering a broad set of functions relevant for 
carcinogenesis, instead of focusing on a specific single function. 
However, this interpretation should be treated with caution, 
since little is known about the functions of the variants them-
selves, let alone the combinations.
Increased ORs for the strongest four-variant combinations 
in the combined IfADo-Nijmegen study group were obtained in 
the never as well as the current smokers (Table 3A). The results 
of both four-variant combinations were confirmed in the New 
England and Spanish Bladder Cancer Studies, although ORs 
were numerically lower (but P values still significant; Table 3B), 
which is not unusual for analysis of an independent replication 
series. The strongest interaction of the entire study, the four-
variant combination in never smokers, is characterized by a 
monotonous trend, where each added variant leads to increased 
ORs. However, also other scenarios were obtained. The four-
variant combinations in current and former smokers show a 
non-monotonous trend with a decreased OR by the two-variant 
combination but increased ORs associated with the following 
variants (Table  3A). Such combinations are possible because 
the applied approach searches for the strongest variant com-
bination independently within all two-, three- and four-variant 
combinations—ignoring that a best lower fold combination has 
been found already. Remarkably, the previous set of combined 
variants usually kept stable with increasing numbers of com-
bined variants. So, the switch from a protective two-variant 
combination to a risk combination of three and four variants 
is easily explained: Either low risk genotypes were added to the 
low-risk genotype of the most important variant in the sub-
group (GSTM1 positive for current smokers, rs9642880[GG, GT] for 
former smokers) or vice versa high-risk genotypes were com-
bined (Table 3A). Importantly, the four-variant combinations as 
well as the non-monotonous trend were confirmed in the New 
England and Spanish Bladder Cancer Studies (Table 3B).
The variants of the best four-variant combination of the 
subgroup of ever smokers showed no overlap with that of the 
never smokers. In smokers, the strongest variant of the four-
variant combination was the GSTM1 deletion. GSTM1 is known 
to be involved in detoxification of cigarette smoke carcinogens 
(8, 33–35). Already in previous publications, the relevance of this 
polymorphism has been demonstrated particularly in smokers 
and individuals occupationally exposed to polycyclic aromatic 
hydrocarbons (8, 11, 36). Interestingly, after cessation of occu-
pational and/or environmental exposure to polycyclic aromatic 
hydrocarbons, the GSTM1 polymorphism was no longer relevant 
(37). The previous interaction analysis of the IfADo case–control 
series comprising seven of the investigated polymorphisms also 
identified the GSTM1 deletion as the most important variant in 
smokers (12). The second variant in the four-variant ever smoker 
combination was rs9642880, a variant approximately 30 000 
bases upstream of MYC which has been reported to be associ-
ated with RNA levels of the oncogene (16, 31, 38). The biological 
function of the third and the fourth variant in the combination, 
the glycoprotein PSCA and the microtubule regulating TACC3 
variants rs2294008 and rs798766 in relation to bladder carcino-
genesis is still not fully understood (17, 31, 39–43). Interactions of 
the GSTM1 deletion, rs9642880 and rs2294008 but not rs798766 
with smoking habits have also been found in a large UBC study 
(3942 cases, 5680 controls) (11). Missense SNP rs2294008 alters 
the PSCA start codon and results in less promoter activity but 
more mRNA (39, 40). PSCA owning an androgen responsive ele-
ment in its promoter region influences PSCA expression (44). It 
is hypothesized that gender-specific UBC risk might be modu-
lated via androgen responsive element-depending PSCA tran-
scription activity in presence of rs2294008. However, relevant 
signalling pathways remain unclear (41). The functional role of 
the TACC3 intron SNP rs798766 is still unclear (17, 31). TACC3 
is a centrosomal adaptor protein that is involved in spindle 
microtubule dynamics during cell division (42, 43). In particu-
lar, TACC3 protein complexes seem to be essential for mitotic 
spindle assembly and dynamics and, hence, for prevention of 
genomic instability (42, 43). However, the observed association 
of rs798766 with UBC risk might also be due to the nearby fibro-
blast growth factor receptor 3 (FGFR3) gene. Fibroblast growth fac-
tor receptors play a key role in activation of signalling pathways, 
for instance, the RAS/MAPK, phospholipase C, gamma 1 (PLCγ1), 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and sig-
nal transducer and activator of transcription pathways that 
regulate proliferation, migration and differentiation (45). Point 
mutations in the FGFR3 gene and increased expression of the 
variant gene are common in low-grade non-invasive papillary 
urothelial bladder carcinomas (45–47). Overexpression of wild-
type FGFR3 is more common in invasive than in non-invasive 
tumors (45, 47). Recently, FGFR3-TACC3 gene fusions have been 
detected in UBC as well as glioblastoma patients and cell lines 
(46–48). The fusion seems to result in a loss of the C-terminus of 
FGFR3 and an overexpression of the FGFR3-TACC3 fusion product 
(47, 48). The protein seems to be highly oncogenic in vivo and 
in vitro and can be assumed to induce signalling via the MAPK 
pathway in urothelial cells (47, 48).
Downloaded from https://academic.oup.com/carcin/article-abstract/38/12/1167/4259368
by Semmelweis University user
on 27 December 2017
1178 | Carcinogenesis, 2017, Vol. 38, No. 12
It should be considered that differences in variant combina-
tions were not only observed between ever and never smokers 
but also between current and former smokers. The subgroup of 
former smokers lost the “smoker variant” GSTM1 in their best 
four-variant combination. Instead, the “never smoker SNP” 
rs8102137 5.8  kb upstream CCNE1 occurs in the best four-var-
iant combination of former smokers. The SNP rs9642880 near 
MYC is the strongest variant in the subgroup of former smok-
ers. It is not present in the best four-variant combination of 
current smokers, nor of never smokers. However, it should be 
taken into account that this four-variant combination identi-
fied in the combined IfADo-Nijmegen case–control series was 
not confirmed in the replication series and should therefore be 
discussed with caution. Reasons for the discrepant result may 
be the general heterogeneity of the subgroup of former smok-
ers, differences in definition and determination of a status as 
a former smoker which is associated with a higher degree of 
uncertainty than in case of current or never smokers. Or this 
observation could be a chance finding.
In conclusion, the present logistic regression based approach 
demonstrated that specific combinations of three to four vari-
ants confer UBC risk. The highest unadjusted OR was obtained 
for a four-variant combination in the subgroup of never smok-
ers (OR = 2.59). Importantly, this four-variant combination was 
confirmed in an independent case–control series. Moreover, 
different SNP combinations were obtained for current smok-
ers (OR = 1.61) and former smokers (OR = 2.13). The dominant 
SNP for never smokers is rs1014971 near APOBEC3A. The most 
important “smoker variant” is GSTM1, while former smok-
ers shift to rs9642880 near MYC. The study demonstrates the 
strength of logistic regression approaches for SNP interactions 
that identify specific interaction profiles. This present study fur-
ther supports the concept, according to which individual poly-
morphisms add only little to overall UBC risk, but the combined 
presence of many individually weak SNPs leads to substantially 
increased ORs (3).
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